Given the constitutive expression of Smyd-2 in hippocampal neurons and its quick-acting Nrf-2-dependent curative pathway, the regimen of Smyd-2-related compounds will be viable clinically against ischemic stroke. The gene discussed is NFE2L2; the disease is ischemic stroke.